From: Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study
Exposure | Methods | nSNP | OR (95%CI) | P |
---|---|---|---|---|
Activated & secreting CD4 regulatory T cell %CD4 + T cell | MR Egger | 4 | 0.78 (0.29–2.07) | 6.69 × 10–1 |
Weighted median | 4 | 0.73 (0.48–1.13) | 1.62 × 10–1 | |
Inverse variance weighted | 4 | 0.68 (0.48–0.96) | 2.92 × 10–2 | |
Simple mode | 4 | 0.76 (0.43–1.35) | 4.18 × 10–1 | |
Weighted mode | 4 | 0.76 (0.45–1.31) | 3.99 × 10–1 | |
CD4-CD8- T cell %T cell | MR Egger | 3 | 0.92 (0.07–11.73) | 9.59 × 10–1 |
Weighted median | 3 | 1.81 (1.16–2.85) | 9.65 × 10–3 | |
Inverse variance weighted | 3 | 1.61 (1.02–2.55) | 4.07 × 10–2 | |
Simple mode | 3 | 1.95 (1.02–3.72) | 1.82 × 10–1 | |
Weighted mode | 3 | 1.91 (1.16–3.13) | 1.25 × 10–1 | |
HLA DR on CD14 + CD16 + monocyte | MR Egger | 5 | 0.93 (0.42–2.07) | 8.65 × 10–1 |
Weighted median | 5 | 0.86 (0.72–1.02) | 8.31 × 10–2 | |
Inverse variance weighted | 5 | 0.84 (0.71–0.99) | 3.92 × 10–2 | |
Simple mode | 5 | 0.68 (0.47–0.96) | 9.71 × 10–2 | |
Weighted mode | 5 | 0.87 (0.71–1.06) | 2.43 × 10–1 | |
BAFF-R on IgD- CD38 + B cell | MR Egger | 3 | 0.71 (0.38–1.34) | 4.86 × 10–1 |
Weighted median | 3 | 0.73 (0.55–0.97) | 2.78 × 10–2 | |
Inverse variance weighted | 3 | 0.69 (0.53–0.89) | 5.74 × 10–3 | |
Simple mode | 3 | 0.72 (0.49–1.07) | 2.44 × 10–1 | |
Weighted mode | 3 | 0.73 (0.53–1.00) | 1.86 × 10–1 | |
CD19 on IgD + CD24- B cell | MR Egger | 3 | 1.01 (0.17 − 5.80) | 9.96 × 10–1 |
Weighted median | 3 | 0.62 (0.37 − 1.04) | 7.16 × 10–2 | |
Inverse variance weighted | 3 | 0.59 (0.37 − 0.95) | 2.87 × 10–2 | |
Simple mode | 3 | 0.63 (0.30 − 1.32) | 3.46 × 10–1 | |
Weighted mode | 3 | 0.63 (0.35 − 1.12) | 2.55 × 10–1 |